Clinical trials in brain tumor surgery

Neuroimaging Clinics of North America

Volumn 20, Issue 3, 2010, Pages 409-424

  Hoover, Jason M ^a   Chang, Susan M ^b   Parney, Ian F ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brain tumor; Central nervous system; Cytoreductive surgery; Gliomas

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; CARMUSTINE; CERADENOVEC; CEREPRO; GANCICLOVIR; N ACETYLASPARTIC ACID; ONCOLYTIC MEASLES VIRUS; ONCOLYTIC VIRUS; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ASTROCYTOMA; BRACHYTHERAPY; BRAIN ELECTROPHYSIOLOGY; BRAIN MAPPING; BRAIN TUMOR; CANCER GRADING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONVECTION ENHANCED DELIVERY; CRANIOTOMY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC ACCURACY; DIFFUSION TENSOR IMAGING; DRUG DELIVERY SYSTEM; EVIDENCE BASED MEDICINE; FLUORESCENCE ANALYSIS; GLIOBLASTOMA; GLIOMA; HUMAN; IMAGE ANALYSIS; INTERVENTIONAL MAGNETIC RESONANCE IMAGING; NEEDLE BIOPSY; NEURONAVIGATION; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STEREOTACTIC BIOPSY; SUICIDE GENE THERAPY; SURGICAL TECHNIQUE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

BIOPSY, NEEDLE; BRACHYTHERAPY; BRAIN; BRAIN MAPPING; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MONITORING, INTRAOPERATIVE; NEUROSURGICAL PROCEDURES; STEREOTAXIC TECHNIQUES;

EID: 77955561640     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nic.2010.04.006     Document Type: Review

References (114)

1. Davis F.G., Kupelian V., Freels S., et al. Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro Oncol 2001, 3(3):152-158.
2. Wrensch M., Minn Y., Chew T., et al. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 2002, 4(4):278-299.
3. Bernstein M., Parrent A.G. Complications of CT-guided stereotactic biopsy of intra-axial brain lesions. J Neurosurg 1994, 81(2):165-168.
4. Kongkham P.N., Knifed E., Tamber M.S., et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing procedure. Can J Neurol Sci 2008, 35(1):79-84.
5. McGirt M.J., Woodworth G.F., Coon A.L., et al. Independent predictors of morbidity after image-guided stereotactic brain biopsy: a risk assessment of 270 cases. J Neurosurg 2005, 102(5):897-901.
6. Owen C.M., Linskey M.E. Frame-based stereotaxy in a frameless era: current capabilities, relative role, and the positive- and negative predictive values of blood through the needle. J Neurooncol 2009, 93(1):139-149.
7. Jackson R.J., Fuller G.N., Abi-Said D., et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol 2001, 3(3):193-200.
8. Woodworth G.F., McGirt M.J., Samdani A., et al. Frameless image-guided stereotactic brain biopsy procedure: diagnostic yield, surgical morbidity, and comparison with the frame-based technique. J Neurosurg 2006, 104(2):233-237.
9. Air E.L., Leach J.L., Warnick R.E., et al. Comparing the risks of frameless stereotactic biopsy in eloquent and noneloquent regions of the brain: a retrospective review of 284 cases. J Neurosurg 2009, 111(4):820-824.
10. Smith J.S., Quinones-Hinojosa A., Barbaro N.M., et al. Frame-based stereotactic biopsy remains an important diagnostic tool with distinct advantages over frameless stereotactic biopsy. J Neurooncol 2005, 73(2):173-179.
11. Quinones-Hinojosa A., Ware M.L., Sanai N., et al. Assessment of image guided accuracy in a skull model: comparison of frameless stereotaxy techniques vs. frame-based localization. J Neurooncol 2006, 76(1):65-70.
12. Kreth F.W., Warnke P.C., Ostertag C.B. Progress in malignant glioma. J Neurosurg 2004, 100:1132-1133.
13. Brown P.D., Maurer M.J., Rummans T.A., et al. A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005, 57(3):495-504. [discussion: 495-504].
14. Buckner J.C., Schomberg P.J., McGinnis W.L., et al. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer 2001, 92(2):420-433.
15. Keles G.E., Anderson B., Berger M.S. The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 1999, 52(4):371-379.
16. Kiwit J.C., Floeth F.W., Bock W.J. Survival in malignant glioma: analysis of prognostic factors with special regard to cytoreductive surgery. Zentralbl Neurochir 1996, 57(2):76-88.
17. Lacroix M., Abi-Said D., Fourney D.R., et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001, 95(2):190-198.
18. Lamborn K., Chang S., Prados M. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol 2004, 6:227-235.
19. Laws E.R., Parney I.F., Huang W., et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 2003, 99(3):467-473.
20. Mohan D.S., Suh J.H., Phan J.L., et al. Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution. Int J Radiat Oncol Biol Phys 1998, 42(5):981-987.
21. Nitta T., Sato K. Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas. Cancer 1995, 75:2727-2731.
22. Stummer W., Pichlmeier U., Meinel T., et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006, 7(5):392-401.
23. Nomiya T., Nemoto K., Kumabe T., et al. Prognostic significance of surgery and radiation therapy in cases of anaplastic astrocytoma: retrospective analysis of 170 cases. J Neurosurg 2007, 106(4):575-581.
24. Quigley M.R., Flores N., Maroon J.C., et al. Value of surgical intervention in the treatment of glioma. Stereotact Funct Neurosurg 1995, 65(1-4):171-175.
25. Slotman B.J., Kralendonk J.H., van Alphen H.A., et al. Hypofractionated radiation therapy in patients with glioblastoma multiforme: results of treatment and impact of prognostic factors. Int J Radiat Oncol Biol Phys 1996, 34(4):895-898.
26. Stark A.M., Nabavi A., Mehdorn H.M., et al. Glioblastoma multiforme-report of 267 cases treated at a single institution. Surg Neurol 2005, 63(2):162-169. [discussion: 169].
27. Albert F.K., Forsting M., Sartor K., et al. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 1994, 34(1):45-60. [discussion: 1].
28. Ammirati M., Vick N., Liao Y.L., et al. Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 1987, 21(2):201-206.
29. Devaux B.C., O'Fallon J.R., Kelly P.J. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 1993, 78(5):767-775.
30. Jeremic B., Grujicic D., Antunovic V., et al. Hyperfractionated radiation therapy followed by multiagent chemotherapy in patients with malignant glioma: a phase II study. Int J Radiat Oncol Biol Phys 1994, 30:1179-1185.
31. Kelly P.J., Hunt C. The limited value of cytoreductive surgery in elderly patients with malignant gliomas. Neurosurgery 1994, 34(1):62-66. [discussion: 66-7].
32. Ushio Y., Kochi M., Hamada J., et al. Effect of surgical removal on survival and quality of life in patients with supratentorial glioblastoma. Neurol Med Chir (Tokyo) 2005, 45(9):454-460. [discussion: 460-1].
33. Vuorinen V., Hinkka S., Farkkila M., et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien) 2003, 145(1):5-10.
34. Shibamoto Y., Yamashita J., Takahashi M., et al. Supratentorial malignant glioma: an analysis of radiation therapy in 178 cases. Radiother Oncol 1990, 18(1):9-17.
35. Simpson J.R., Horton J., Scott C., et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993, 26(2):239-244.
36. Vecht C.J., Avezaat C.J., van Putten W.L., et al. The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients. J Neurol Neurosurg Psychiatry 1990, 53(6):466-471.
37. Winger M.J., Macdonald D.R., Cairncross J.G. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg 1989, 71(4):487-493.
38. Shinoda J., Sakai N., Murase S., et al. Selection of eligible patients with supratentorial glioblastoma multiforme for gross total resection. J Neurooncol 2001, 52(2):161-171.
39. Keles G.E., Chang E.F., Lamborn K.R., et al. Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. J Neurosurg 2006, 105(1):34-40.
40. Pope W.B., Sayre J., Perlina A., et al. MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 2005, 26(10):2466-2474.
41. Schmidt M., Berger M., Lamborn K., et al. Repeated operations for infiltrative low-grade gliomas without intervening therapy. J Neurosurg 2003, 98:1165-1169.
42. Frappaz D., Chinot O., Bataillard A., et al. Summary version of the standards, options and recommendations for the management of adult patients with intracranial glioma (2002). Br J Cancer 2003, 89(Suppl 1):S73-S83.
43. Team L-GGG Practice parameters in adults with suspected or known supratentorial nonoptic pathway low-grade glioma. Neurosurg Focus 1998, 4:e10.
44. Keles G., Lamborn K., Berger M. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg 2001, 95:735-745.
45. Claus E., Horlacher A., Hsu L., et al. Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer 2005, 103:1227-1233.
46. Johannesen T., Langmark F., Lote K. Progress in long-term survival in adult patients with supratentorial low-grade gliomas: a population-based study of 993 patients in whom tumors were diagnosed between 1970 and 1993. J Neurosurg 2003, 99:854-862.
47. Leighton C., Fisher B., Bauman G., et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 1997, 15(4):1294-1301.
48. Nakamura M., Konishi N., Tsunoda S., et al. Analysis of prognostic and survival factors related to treatment of low-grade astrocytomas in adults. Oncology 2000, 58(2):108-116.
49. Philippon J.H., Clemenceau S.H., Fauchon F.H., et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery 1993, 32(4):554-559.
50. Rajan B., Pickuth D., Ashley S., et al. The management of histologically unverified presumed cerebral gliomas with radiotherapy. Int J Radiat Oncol Biol Phys 1994, 28(2):405-413.
51. Shaw E., Arusell R., Scheithauer B., et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002, 20(9):2267-2276.
52. van Veelen M., Avezaat C., Kros J., et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry 1998, 64:581-587.
53. Yeh S.A., Ho J.T., Lui C.C., et al. Treatment outcomes and prognostic factors in patients with supratentorial low-grade gliomas. Br J Radiol 2005, 78(927):230-235.
54. Smith J.S., Chang E.F., Lamborn K.R., et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 2008, 26(8):1338-1345.
55. Shaw E.G., Berkey B., Coons S.W., et al. Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade-glioma: results of a prospective clinical trial. J Neurosurg 2008, 109(5):835-841.
56. Yeh D.D., Warnick R.E., Ernst R.J. Management strategy for adult patients with dorsal midbrain gliomas. Neurosurgery 2002, 50(4):735-738. [discussion: 738-40].
57. Chang S.M., Nelson S., Vandenberg S., et al. Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma. J Neurooncol 2009, 92(3):401-415.
58. Dowling C., Bollen A.W., Noworolski S.M., et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. AJNR Am J Neuroradiol 2001, 22(4):604-612.
59. Lupo J.M., Cha S., Chang S.M., et al. Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. AJNR Am J Neuroradiol 2005, 26(6):1446-1454.
60. Kwong K., Belliveau J., Chesler D., et al. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acad Sci U S A 1992, 89:5675-5679.
61. Basser P., Jones D. Diffusion-tensor MRI: theory, experimental design and data analysis - a technical review. NMR Biomed 2002, 15:456-467.
62. Binder J., Rao S., Hammeke T., et al. Lateralized human brain language systems demonstrated by task subtraction functional magnetic resonance imaging. Arch Neurol 1995, 52:593-601.
63. Bittar R., Olivier A., Sadikot A., et al. Presurgical motor and somatosensory cortex mapping with functional magnetic resonance imaging and positron emission tomography. J Neurosurg 1999, 91:915-921.
64. Nimsky C., Ganslandt O., Fahlbusch R. Comparing 0.2 tesla with 1.5 tesla intraoperative magnetic resonance imaging analysis of setup, workflow, and efficiency. Acad Radiol 2005, 12(9):1065-1079.
65. Berman J., Berger M., Mukherjee P., et al. Diffusion-tensor imaging-guided tracking of fibers of the pyramidal tract combined with intraoperative cortical stimulation mapping in patients with gliomas. J Neurosurg 2004, 101:66-72.
66. Roberts T., Disbrow E., Roberts H., et al. Quantification and reproducibility of tracking cortical extent of activation by use of functional MR imaging and magnetoencephalography. AJNR Am J Neuroradiol 2000, 21:1377-1387.
67. Nimsky C., Ganslandt O., Hastreiter P., et al. Preoperative and intraoperative diffusion tensor imaging-based fiber tracking in glioma surgery. Neurosurgery 2007, 61(Suppl 1):178-185. [discussion: 86].
68. Nagarajan S., Kirsch H., Lin P., et al. Preoperative localization of hand motor cortex by adaptive spatial filtering of magnetoencephalography data. J Neurosurg 2008, 109(2):228-237.
69. Gaetz W., Cheyne D., Rutka J.T., et al. Presurgical localization of primary motor cortex in pediatric patients with brain lesions by the use of spatially filtered magnetoencephalography. Neurosurgery 2009, 64(Suppl 3):177-185. [discussion: 186].
70. Berger M.S., Hadjipanayis C.G. Surgery of intrinsic cerebral tumors. Neurosurgery 2007, 61(Suppl 1):279-304. [discussion: 305].
71. Litofsky N.S., Bauer A.M., Kasper R.S., et al. Image-guided resection of high-grade glioma: patient selection factors and outcome. Neurosurg Focus 2006, 20(4):E16.
72. Keles G., Lamborn K., Berger M. Coregistration accuracy and detection of brain shift using intraoperative sononavigation during resection of hemispheric tumors. Neurosurgery 2003, 53:556-562.
73. Ram Z., Hadani M. Intraoperative imaging-MRI. Acta Neurochir Suppl 2003, 88:1-4.
74. Benveniste R., Germano I.M. Evaluation of factors predicting accurate resection of high-grade gliomas by using frameless image-guided stereotactic guidance. Neurosurg Focus 2003, 14(2):e5.
75. Nimsky C., Ganslandt O., Tomandl B., et al. Low-field magnetic resonance imaging for intraoperative use in neurosurgery: a 5-year experience. Eur Radiol 2002, 12(11):2690-2703.
76. Senft C., Seifert V., Hermann E., et al. Usefulness of intraoperative ultra low-field magnetic resonance imaging in glioma surgery. Neurosurgery 2008, 63(4 Suppl 2):257-266. [discussion: 266-7].
77. Schneider J.P., Trantakis C., Rubach M., et al. Intraoperative MRI to guide the resection of primary supratentorial glioblastoma multiforme-a quantitative radiological analysis. Neuroradiology 2005, 47(7):489-500.
78. Kaibara T., Saunders J.K., Sutherland G.R. Advances in mobile intraoperative magnetic resonance imaging. Neurosurgery 2000, 47(1):131-137. [discussion: 137-8].
79. Hatiboglu M.A., Weinberg J.S., Suki D., et al. Impact of intraoperative high-field magnetic resonance imaging guidance on glioma surgery: a prospective volumetric analysis. Neurosurgery 2009, 64(6):1073-1081. [discussion: 1081].
80. Bergsneider M., Sehati N., Villablanca P., et al. Mahaley Clinical Research Award: extent of glioma resection using low-field (0.2 T) versus high-field (1.5 T) intraoperative MRI and image-guided frameless neuronavigation. Clin Neurosurg 2005, 52:389-399.
81. Penfield W., Boldrey E. Somatic motor and sensory representation in the cerebral cortex of man as studied by electrical stimulation. Brain 1937, 60:389-443.
82. Berger M., Cohen W., Ojemann G. Correlation of motor cortex brain mapping data with magnetic resonance imaging. J Neurosurg 1990, 72:383-387.
83. Ojemann G., Ojemann J., Lettich E., et al. Cortical language localization in left, dominant hemisphere. An electrical stimulation mapping investigation in 117 patients. J Neurosurg 1989, 71(3):316-326.
84. Skirboll S., Ojemann G., Berger M., et al. Functional cortex and subcortical white matter located within gliomas. Neurosurgery 1996, 38:678-684.
85. Keles G., Lundin D., Lamborn K., et al. Intraoperative subcortical stimulation mapping for hemispherical perirolandic gliomas located within or adjacent to the descending motor pathways: evaluation of morbidity and assessment of functional outcome in 294 patients. J Neurosurg 2004, 100:369-375.
86. Sanai N., Mirzadeh Z., Berger M.S. Functional outcome after language mapping for glioma resection. N Engl J Med 2008, 358(1):18-27.
87. Stummer W., Novotny A., Stepp H., et al. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 2000, 93(6):1003-1013.
88. Stummer W., Reulen H.J., Meinel T., et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008, 62(3):564-576. [discussion: 576].
89. McDermott M., Berger M., Kunwar S., et al. Stereotactic radiosurgery and interstitial brachytherapy for glial neoplasms. J Neurooncol 2004, 69:83-100.
90. Laperriere N.J., Leung P.M., McKenzie S., et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 1998, 41(5):1005-1011.
91. Larson D., Suplica J., Chang S., et al. Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol 2004, 6:119-126.
92. Patel S., Breneman J., Warnick R., et al. Permanent iodine-125 interstitial implants for the treatment of recurrent glioblastoma multiforme. Neurosurgery 2000, 46:1123-1128.
93. Tatter S., Shaw E., Rosenblum M., et al. An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial. J Neurosurg 2003, 99:297-303.
94. Chan T.A., Weingart J.D., Parisi M., et al. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy. Int J Radiat Oncol Biol Phys 2005, 62(4):1133-1139.
95. Gabayan A.J., Green S.B., Sanan A., et al. GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Neurosurgery 2006, 58(4):701-709. [discussion: 9].
96. Walter K.A., Tamargo R.J., Olivi A., et al. Intratumoral chemotherapy. Neurosurgery 1995, 37(6):1128-1145.
97. Brem H., Mahaley M.S., Vick N.A., et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 1991, 74(3):441-446.
98. Westphal M., Hilt D., Bortey E., et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003, 5:79-88.
99. Westphal M., Ram Z., Riddle V., et al. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006, 148:269-275.
100. Attenello F.J., Mukherjee D., Datoo G., et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 2008, 15(10):2887-2893.
101. Bobo R.H., Laske D.W., Akbasak A., et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 1994, 91(6):2076-2080.
102. Lieberman D.M., Laske D.W., Morrison P.F., et al. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 1995, 82(6):1021-1029.
103. Vogelbaum M.A., Sampson J.H., Kunwar S., et al. Convection-enhanced delivery of cintredekin besudotox (Interleukin-13-Pe38qqr) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery 2007, 61(5):1031-1037.
104. Kunwar S., Prados M.D., Chang S.M., et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007, 25(7):837-844.
105. Parney I.F., Kunwar S., McDermott M., et al. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg 2005, 102(2):267-275.
106. Sampson J., Brady M., Petry N., et al. Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery 2007, 60(2 Suppl 1):ONS89-ONS98.
107. Kaiser M.G., Parsa A.T., Fine R.L., et al. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery 2000, 47(6):1391-1398. [discussion: 1398-9].
108. Forsyth P., Roldan G., George D., et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 2008, 16(3):627-632.
109. Chiocca E.A., Abbed K.M., Tatter S., et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 2004, 10(5):958-966.
110. Liu T.C., Galanis E., Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract 2007, 4(2):101-117.
111. Liu C., Sarkaria J.N., Petell C.A., et al. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin Cancer Res 2007, 13(23):7155-7165.
112. Phuong L.K., Allen C., Peng K.W., et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 2003, 63(10):2462-2469.
113. Myers R., Harvey M., Kaufmann T.J., et al. Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas. Hum Gene Ther 2008, 19(7):690-698.
114. Ram Z, Westphal M, Warnke P, et al. Treatment of primary high-grade glioma with sitimagene ceradenovec (Cerepro) and ganciclovir gene medicine: update of phase III results. Abstract presentation at the 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors.